Quest Competitors

Pink Sheets . USA . 
Stock . Quest PharmaTech
QPTFF Stock  USD 0.01  0.00  0.00%   
Quest PharmaTech competes with Sino Biopharmaceutica, Defence Therapeutics, Enlivex Therapeutics, and Achilles Therapeutics; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Quest PharmaTech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Quest PharmaTech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Quest PharmaTech Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Quest PharmaTech competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.010.01
Details
Intrinsic
Valuation
LowRealHigh
0.010.010.01
Details
Naive
Forecast
LowNextHigh
0.010.010.01
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.010.010.01
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Quest PharmaTech. Your research has to be compared to or analyzed against Quest PharmaTech's peers to derive any actionable benefits. When done correctly, Quest PharmaTech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Quest PharmaTech.

Quest PharmaTech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Quest PharmaTech and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Quest and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Quest PharmaTech does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RGBP
+ 0.74
ENLV
LVCLF
+ 0.65
SBHMY
ACHL
+ 0.48
DTCFF
RGBP
+ 0.36
SBHMY
RGBP
+ 0.18
LVCLF
ENLV
+ 0.17
SBHMY
  
High negative correlations   
ACHL
- 0.81
LVCLF
ACHL
- 0.67
SBHMY
DTCFF
- 0.49
SBHMY
ACHL
- 0.42
RGBP
ACHL
- 0.32
ENLV
LVCLF
- 0.3
DTCFF

Risk-Adjusted Indicators

There is a big difference between Quest Pink Sheet performing well and Quest PharmaTech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Quest PharmaTech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SBHMY  0.80 (0.32) 0.00  1.88  0.00 
 0.00 
 0.14 
(3.80)
 9.00 
DTCFF  4.48  1.40  0.08  5.59  4.96 
(17.85)
 14.75 
(4.55)
 85.59 
ENLV  2.99 (0.32) 0.00  1.24  0.00 
 0.00 
 6.54 
(5.60)
 26.52 
LVCLF  3.94  0.40  0.00  0.36  0.00 
 0.00 
 0.00 
 0.00 
 112.50 
MCET  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
HESG  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MYMX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RGBP  15.16  0.86  0.03 (0.20) 16.80 
(19.09)
 48.92 
(29.91)
 159.27 
ACHL  1.37  0.23  0.07 (2.97) 1.22 
(2.38)
 2.59 
(2.86)
 19.72 
All Fundamental Data

Quest PharmaTech Competitive Analysis

The better you understand Quest PharmaTech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Quest PharmaTech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Quest PharmaTech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
QPTFF SBHMY DTCFF ENLV LVCLF MYMX RGBP ACHL
 0.00 
 0.01 
Quest
 0.14 
 7.25 
Sino
 7.41 
 0.75 
Defence
 1.77 
 1.11 
Enlivex
 26.47 
 0 
Living
 0.00 
 0 
Mymetics
 11.29 
 0.06 
Regen
 0.88 
 1.12 
Achilles
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Out of control
Very risky
Out of control
Very steady
Out of control
Dangerous
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Good
Very Weak
Insignificant
Very Weak
Insignificant
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
High
Low
Low
Quite High
Very High
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Hold
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Hold
Current Ratio
0.52 X
1.55 X
0.61 X
15.44 X
17.84 X
0.01 X
0.05 X
11.45 X
Net Asset
91.03 M
60.54 B
719.67 K
36.83 M
4.27 M
7.63 M
559 K
161.46 M
Profit Margin
N/A
0.29 %
N/A
N/A
N/A
N/A
6.09 %
N/A
EBITDA
(84.99 M)
19.87 B
(7.32 M)
(28.22 M)
(2.38 M)
(1.96 M)
2.44 M
(70.44 M)
Current Valuation
7.81 M
10.34 B
60.32 M
646.39 K
12.53 M
83.16 M
22.4 M
(34.59 M)
Price To Book
0.19 X
2.53 X
36.71 X
0.92 X
6.96 X
N/A
N/A
0.45 X
Operating Margin
N/A
0.16 %
N/A
N/A
(428.70) %
(1.76) %
(2.96) %
N/A
Five Year Return
N/A
0.99 %
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
(112.09 M)
(67 M)
(81.98 M)
(17.78 M)
(259.95 M)
Current Asset
N/A
N/A
N/A
6 M
6 M
1.38 M
171 K
N/A
Beta
0.84
0.51
N/A
1.11
0.27
0.24
3.36
1.34
Number Of Employees
11
25.55 K
4
N/A
15
9
1
204
Shares Outstanding
169.13 M
940.69 M
37.85 M
21.99 M
1.29 B
303.76 M
5.05 B
41.1 M
Cash Flow From Operations
(170.78 K)
5.37 B
(6.04 M)
(23.52 M)
(2.04 M)
(1.7 M)
(606.92 K)
(48.45 M)
Annual Yield
N/A
0.03 %
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
1000 K
5.21 B
N/A
1.03 M
228.44 K
162 K
1.58 M
4.62 M
Return On Equity
-0.62
0.29
-4.15
-0.61
-0.72
N/A
N/A
-0.44
Z Score
7.2
1.2
-33.0
N/A
5.4
-1.4
-26.6
N/A
Return On Asset
-0.0038
0.0451
-1.79
-0.27
-0.31
-0.14
-0.76
-0.27
Book Value Per Share
0.52 X
32.70 X
(0.03) X
1.62 X
0 X
(0.21) X
(0) X
3.46 X
Number Of Shares Shorted
N/A
N/A
N/A
122.98 K
N/A
N/A
N/A
122.36 K
Current Liabilities
N/A
N/A
N/A
671.32 K
1000 K
51.24 M
649 K
N/A
Total Asset
91.03 M
60.54 B
719.67 K
36.83 M
4.27 M
7.63 M
559 K
161.46 M
Debt To Equity
0.01 %
0.31 %
N/A
0.08 %
0.10 %
N/A
1.25 %
0.04 %
Last Dividend Paid
N/A
0.083
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
N/A
N/A
0.56 X
N/A
N/A
N/A
1.69 X
Target Price
N/A
N/A
N/A
9.5
N/A
N/A
N/A
0.5
Shares Owned By Institutions
N/A
N/A
N/A
18.80 %
N/A
N/A
N/A
59.29 %
Market Capitalization
12.89 M
10.88 B
143.45 M
24.41 M
9.81 M
5.47 M
10.1 M
47.84 M
Price To Earning
0.14 X
8.95 X
N/A
(11.97) X
(31.67) X
(2.40) X
N/A
0.49 X
Price To Earnings To Growth
N/A
0.53 X
N/A
N/A
N/A
N/A
N/A
(0.31) X
Price To Sales
N/A
0.41 X
N/A
N/A
5,587 X
12.17 X
89.73 X
N/A
Net Income
(85.04 M)
14.61 B
(7.34 M)
(29.07 M)
(1.96 M)
(4.73 M)
2.44 M
(69.94 M)
Earnings Per Share
(0.39) X
1.15 X
(0.15) X
(0.98) X
(0) X
(0.02) X
N/A
(1.66) X
Shares Owned By Insiders
16.80 %
N/A
5.26 %
5.73 %
33.99 %
54.90 %
0.06 %
6.51 %
Revenue
N/A
26.86 B
N/A
N/A
3.4 K
3 K
235.52 K
N/A
Working Capital
N/A
N/A
N/A
27.7 M
5 M
(49.86 M)
(478 K)
128.64 M
Cash And Equivalents
518.76 K
15.67 B
506.7 K
62.48 M
4.24 M
350 K
110.99 K
201.6 M
Cash Per Share
N/A
16.96 X
0.01 X
3.40 X
N/A
N/A
N/A
4.94 X
Gross Profit
N/A
21.53 B
N/A
N/A
3.4 K
(545 K)
235.52 K
N/A
Day Typical Price
0.0133
7.25
0.77
1.09
0.004
0.001
0.0647
1.12
Accumulation Distribution
N/A
N/A
1955.56
0.0625
0.64
N/A
2746.49
1667.13
Market Facilitation Index
N/A
N/A
0.0
0.07
0.0045
N/A
N/A
N/A
Daily Balance Of Power
0.0
9.2 T
(1.00)
(0.29)
(0.20)
0.0
(1.00)
(0.33)
Period Momentum Indicator
N/A
0.01
(0.06)
(0.02)
(0.0009)
N/A
(0.01)
(0.01)
Rate Of Daily Change
1.0
1.0
0.93
0.98
0.74
1.0
0.89
0.99
Day Median Price
0.0133
7.25
0.78
1.09
0.0048
0.001
0.0661
1.13
Price Action Indicator
N/A
0.005
(0.06)
0.015
(0)
N/A
(0.01)
(0.01)
Coefficient Of Variation
N/A
(511.28)
779.4
(1,429)
3083.42
N/A
4012.14
1094.02
Mean Deviation
N/A
0.8046
4.48
2.99
3.94
N/A
15.16
1.37
Jensen Alpha
N/A
(0.32)
1.4
(0.32)
0.4015
N/A
0.8649
0.2292
Total Risk Alpha
N/A
(0.51)
0.221
(0.86)
(1.28)
N/A
(2.02)
(0.05)
Sortino Ratio
N/A
N/A
0.0775
N/A
N/A
N/A
0.0252
0.0665
Downside Variance
N/A
N/A
296.79
N/A
N/A
N/A
399.76
3.97
Standard Deviation
N/A
1.64
11.18
4.8
16.82
N/A
24.25
2.54
Kurtosis
N/A
11.53
24.26
6.65
34.92
N/A
7.06
24.57
Potential Upside
N/A
0.1381
14.75
6.54
N/A
N/A
48.92
2.59
Treynor Ratio
N/A
1.88
5.59
1.24
0.3592
N/A
(0.20)
(2.97)
Maximum Drawdown
N/A
9.0
85.59
26.52
112.5
N/A
159.27
19.72
Variance
N/A
2.7
125.07
23.02
282.97
N/A
587.84
6.47
Market Risk Adjusted Performance
N/A
1.89
5.6
1.25
0.3692
N/A
(0.19)
(2.96)
Risk Adjusted Performance
N/A
(0.16)
0.1164
(0.05)
0.0366
N/A
0.0305
0.0831
Skewness
N/A
(2.74)
3.59
1.53
3.53
N/A
1.86
4.0
Semi Deviation
N/A
N/A
4.96
N/A
N/A
N/A
16.8
1.22
Information Ratio
N/A
(0.26)
0.1194
(0.09)
0.0265
N/A
0.0208
0.0521
Value At Risk
N/A
(3.80)
(4.55)
(5.60)
N/A
N/A
(29.91)
(2.86)
Expected Short fall
N/A
N/A
(17.85)
N/A
N/A
N/A
(19.09)
(2.38)
Downside Deviation
N/A
N/A
17.23
N/A
N/A
N/A
19.99
1.99
Semi Variance
N/A
N/A
24.6
N/A
N/A
N/A
282.14
1.48

Quest PharmaTech Competition Performance Charts

Five steps to successful analysis of Quest PharmaTech Competition

Quest PharmaTech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Quest PharmaTech in relation to its competition. Quest PharmaTech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Quest PharmaTech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Quest PharmaTech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Quest PharmaTech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Quest PharmaTech position

In addition to having Quest PharmaTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Quest Pink Sheet

Quest PharmaTech financial ratios help investors to determine whether Quest Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Quest with respect to the benefits of owning Quest PharmaTech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY